Veradermics, Incorporated (MANE) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $100.38: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: Below-average business quality; Negative price momentum.
Veradermics (MANE) is a clinical-stage biopharmaceutical company developing VDPHL01, an oral extended-release minoxidil tablet for pattern hair loss (PHL) affecting approximately 50 million men and 30 million women in the U.S. The company has no commercial revenue; it is... Read more
Sell if holding. Engine safety override at $100.38: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: RSI 47 mid-range, Bollinger mid-band. Score 5.0/10, moderate confidence.
Passes 5/7 gates (clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.
Recent Developments — Veradermics, Incorporated
Latest news
- Veradermics To Present Two Comparative Analyses Of VDPHL01's Phase 2 Male Data Results Versus Published Data On Efficacy — benzinga May 14, 2026 positive
- Reported Earlier, Veradermics Prices Upsized Public Offering Of 3,843,790 Common Shares At $100 Per Share, Raising ~$384 — benzinga Apr 30, 2026 neutral
- Veradermics Launches Proposed Public Offering Of 3,350,000 Shares Of Common Stock — benzinga Apr 27, 2026 negative
- 12 Health Care Stocks Moving In Monday's Intraday Session — benzinga Apr 27, 2026 neutral
- Crude Oil Gains Over 1%; Verizon Posts Upbeat Earnings — benzinga Apr 27, 2026 neutral
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- HIGHpipelineVDPHL0110-K Item 1A: 'our success will substantially depend on the approval and successful commercialization of VDPHL01, which is our lead product candidate. If we are unable to obtain regulatory approval for, and successfully commercialize, VDPHL01...our business will be materially harmed'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $100.38: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: RSI 47 mid-range, Bollinger mid-band. Prior stop was $93.35. Score 5.0/10, moderate confidence.
Take-profit target: $111.35 (+10.9% upside). Prior stop was $93.35. Stop-loss: $93.35.
Concentration risk — Pipeline: VDPHL01; Quality below floor (2.0 < 4.0).
Veradermics, Incorporated trades at a P/E of N/A (forward -33.4). TrendMatrix value score: 6.0/10. Verdict: Sell.
10 analysts cover MANE with a consensus score of 4.4/5. Average price target: $131.
What does Veradermics, Incorporated do?Veradermics (MANE) is a clinical-stage biopharmaceutical company developing VDPHL01, an oral extended-release minoxidil...
Veradermics (MANE) is a clinical-stage biopharmaceutical company developing VDPHL01, an oral extended-release minoxidil tablet for pattern hair loss (PHL) affecting approximately 50 million men and 30 million women in the U.S. The company has no commercial revenue; it is conducting three pivotal registration-directed trials (two male PHL, one female PHL) funded by $557.8 million total equity proceeds including $294.8 million from its Q1 2026 IPO.